Human methylome studies SRP453184 Track Settings
 
Viral reprogramming of host transcription initiation [B Cell Lymphoma]

Track collection: Human methylome studies

+  All tracks in this collection (463)

Maximum display mode:       Reset to defaults   
Select views (Help):
AMR       CpG methylation ▾       PMD       CpG reads ▾      
Select subtracks by views and experiment:
 All views AMR  CpG methylation  PMD  CpG reads 
experiment
SRX21238929 
SRX21238930 
SRX21238931 
SRX21238932 
SRX21238933 
SRX21238934 
SRX21238935 
SRX21238936 
List subtracks: only selected/visible    all    ()
  experiment↓1 views↓2   Track Name↓3  
hide
 Configure
 SRX21238929  CpG methylation  B Cell Lymphoma / SRX21238929 (CpG methylation)   Schema 
hide
 Configure
 SRX21238930  CpG methylation  B Cell Lymphoma / SRX21238930 (CpG methylation)   Schema 
hide
 Configure
 SRX21238931  CpG methylation  B Cell Lymphoma / SRX21238931 (CpG methylation)   Schema 
hide
 Configure
 SRX21238932  CpG methylation  B Cell Lymphoma / SRX21238932 (CpG methylation)   Schema 
hide
 Configure
 SRX21238933  CpG methylation  B Cell Lymphoma / SRX21238933 (CpG methylation)   Schema 
hide
 Configure
 SRX21238934  CpG methylation  B Cell Lymphoma / SRX21238934 (CpG methylation)   Schema 
hide
 Configure
 SRX21238935  CpG methylation  B Cell Lymphoma / SRX21238935 (CpG methylation)   Schema 
hide
 Configure
 SRX21238936  CpG methylation  B Cell Lymphoma / SRX21238936 (CpG methylation)   Schema 
    

Study title: Viral reprogramming of host transcription initiation
SRA: SRP453184
GEO: not found
Pubmed: not found

Experiment Label Methylation Coverage HMRs HMR size AMRs AMR size PMDs PMD size Conversion Details
SRX21238929 B Cell Lymphoma 0.590 42.8 122063 5188.2 2450 930.8 1365 1054857.9 0.988 title: Bisulfite Seq of latent and reactivated Akata cells; {"isolate": "B cell lymphoma", "age": "4y", "biomaterial_provider": "Kenzo Takada", "collection_date": "1984", "geo_loc_name": "Japan", "sex": "female", "tissue": "B cell lymphoma", "cell_line": "Akata", "cell_type": "B cell lymphoma", "sample_type": "Rep1 Ctl", "treatment": "(-)"}
SRX21238930 B Cell Lymphoma 0.587 47.0 124196 5113.1 2478 931.1 1331 1078693.1 0.990 title: Bisulfite Seq of latent and reactivated Akata cells; {"isolate": "B cell lymphoma", "age": "4y", "biomaterial_provider": "Kenzo Takada", "collection_date": "1984", "geo_loc_name": "Japan", "sex": "female", "tissue": "B cell lymphoma", "cell_line": "Akata", "cell_type": "B cell lymphoma", "sample_type": "Rep2 Ctl", "treatment": "(-)"}
SRX21238931 B Cell Lymphoma 0.591 48.2 126467 5040.0 2504 932.9 1337 1078001.5 0.990 title: Bisulfite Seq of latent and reactivated Akata cells; {"isolate": "B cell lymphoma", "age": "4y", "biomaterial_provider": "Kenzo Takada", "collection_date": "1984", "geo_loc_name": "Japan", "sex": "female", "tissue": "B cell lymphoma", "cell_line": "Akata", "cell_type": "B cell lymphoma", "sample_type": "Rep3 Ctl", "treatment": "(-)"}
SRX21238932 B Cell Lymphoma 0.588 48.4 127068 4992.0 2516 934.9 1332 1081360.9 0.990 title: Bisulfite Seq of latent and reactivated Akata cells; {"isolate": "B cell lymphoma", "age": "4y", "biomaterial_provider": "Kenzo Takada", "collection_date": "1984", "geo_loc_name": "Japan", "sex": "female", "tissue": "B cell lymphoma", "cell_line": "Akata", "cell_type": "B cell lymphoma", "sample_type": "Rep4 Ctl", "treatment": "(-)"}
SRX21238933 B Cell Lymphoma 0.583 47.1 124093 5122.2 2376 926.2 1310 1098735.2 0.988 title: Bisulfite Seq of latent and reactivated Akata cells; {"isolate": "B cell lymphoma", "age": "4y", "biomaterial_provider": "Kenzo Takada", "collection_date": "1984", "geo_loc_name": "Japan", "sex": "female", "tissue": "B cell lymphoma", "cell_line": "Akata", "cell_type": "B cell lymphoma", "sample_type": "Rep1 Ig", "treatment": "anti-IgG"}
SRX21238934 B Cell Lymphoma 0.583 45.8 126353 5033.8 2352 932.6 1328 1088372.8 0.989 title: Bisulfite Seq of latent and reactivated Akata cells; {"isolate": "B cell lymphoma", "age": "4y", "biomaterial_provider": "Kenzo Takada", "collection_date": "1984", "geo_loc_name": "Japan", "sex": "female", "tissue": "B cell lymphoma", "cell_line": "Akata", "cell_type": "B cell lymphoma", "sample_type": "Rep2 Ig", "treatment": "anti-IgG"}
SRX21238935 B Cell Lymphoma 0.585 48.1 126478 5065.2 2593 937.1 1355 1072096.2 0.990 title: Bisulfite Seq of latent and reactivated Akata cells; {"isolate": "B cell lymphoma", "age": "4y", "biomaterial_provider": "Kenzo Takada", "collection_date": "1984", "geo_loc_name": "Japan", "sex": "female", "tissue": "B cell lymphoma", "cell_line": "Akata", "cell_type": "B cell lymphoma", "sample_type": "Rep3 Ig", "treatment": "anti-IgG"}
SRX21238936 B Cell Lymphoma 0.578 45.9 126093 5059.3 2428 925.2 1309 1100778.9 0.991 title: Bisulfite Seq of latent and reactivated Akata cells; {"isolate": "B cell lymphoma", "age": "4y", "biomaterial_provider": "Kenzo Takada", "collection_date": "1984", "geo_loc_name": "Japan", "sex": "female", "tissue": "B cell lymphoma", "cell_line": "Akata", "cell_type": "B cell lymphoma", "sample_type": "Rep4 Ig", "treatment": "anti-IgG"}

Methods

All analysis was done using a bisulfite sequnecing data analysis pipeline DNMTools developed in the Smith lab at USC.

Mapping reads from bisulfite sequencing: Bisulfite treated reads are mapped to the genomes with the abismal program. Input reads are filtered by their quality, and adapter sequences in the 3' end of reads are trimmed. This is done with cutadapt. Uniquely mapped reads with mismatches/indels below given threshold are retained. For pair-end reads, if the two mates overlap, the overlapping part of the mate with lower quality is discarded. After mapping, we use the format command in dnmtools to merge mates for paired-end reads. We use the dnmtools uniq command to randomly select one from multiple reads mapped exactly to the same location. Without random oligos as UMIs, this is our best indication of PCR duplicates.

Estimating methylation levels: After reads are mapped and filtered, the dnmtools counts command is used to obtain read coverage and estimate methylation levels at individual cytosine sites. We count the number of methylated reads (those containing a C) and the number of unmethylated reads (those containing a T) at each nucleotide in a mapped read that corresponds to a cytosine in the reference genome. The methylation level of that cytosine is estimated as the ratio of methylated to total reads covering that cytosine. For cytosines in the symmetric CpG sequence context, reads from the both strands are collapsed to give a single estimate. Very rarely do the levels differ between strands (typically only if there has been a substitution, as in a somatic mutation), and this approach gives a better estimate.

Bisulfite conversion rate: The bisulfite conversion rate for an experiment is estimated with the dnmtools bsrate command, which computes the fraction of successfully converted nucleotides in reads (those read out as Ts) among all nucleotides in the reads mapped that map over cytosines in the reference genome. This is done either using a spike-in (e.g., lambda), the mitochondrial DNA, or the nuclear genome. In the latter case, only non-CpG sites are used. While this latter approach can be impacted by non-CpG cytosine methylation, in practice it never amounts to much.

Identifying hypomethylated regions (HMRs): In most mammalian cells, the majority of the genome has high methylation, and regions of low methylation are typically the interesting features. (This seems to be true for essentially all healthy differentiated cell types, but not cells of very early embryogenesis, various germ cells and precursors, and placental lineage cells.) These are valleys of low methylation are called hypomethylated regions (HMR) for historical reasons. To identify the HMRs, we use the dnmtools hmr command, which uses a statistical model that accounts for both the methylation level fluctations and the varying amounts of data available at each CpG site.

Partially methylated domains: Partially methylated domains are large genomic regions showing partial methylation observed in immortalized cell lines and cancerous cells. The pmd program is used to identify PMDs.

Allele-specific methylation: Allele-Specific methylated regions refers to regions where the parental allele is differentially methylated compared to the maternal allele. The program allelic is used to compute allele-specific methylation score can be computed for each CpG site by testing the linkage between methylation status of adjacent reads, and the program amrfinder is used to identify regions with allele-specific methylation.

For more detailed description of the methods of each step, please refer to the DNMTools documentation.